Tailoring Toxicity Monitoring for ADCs in Metastatic Triple-Negative Breast Cancer

This video was supported by Gilead Sciences, Inc., but editorially independently created by the Oncology Nursing News team.

NP Theresa Stukus and NP Nelli Zafman discuss how the distinct toxicity profiles of available antibody-drug conjugates (ADCs) influence supportive care strategies for patients with metastatic triple-negative breast cancer (mTNBC). The faculty emphasize that proactive monitoring and patient education should be tailored to the specific adverse events associated with each therapy, including gastrointestinal and hematologic toxicities, oral toxicities, ocular surface events, and pulmonary toxicities such as interstitial lung disease. NP Zafman highlights the importance of implementing preventive supportive care measures, reinforcing symptom reporting, and maintaining close clinical surveillance to facilitate early recognition and intervention. The discussion also addresses the role of imaging and careful assessment of subtle changes in respiratory symptoms when monitoring patients receiving therapies associated with pulmonary toxicity. Throughout the conversation, NP Stukus and NP Zafman underscore that individualized toxicity management, patient engagement, and timely multidisciplinary intervention are essential for minimizing complications, maintaining treatment adherence, and optimizing outcomes for patients with metastatic triple-negative breast cancer.